Short-Term Efficacy and Safety of Secukinumab for Ankylosing Spondylitis: A Systematic Review and Meta-Analysis of RCTs

Secukinumab is a novel IL-17A inhibitor that has been confirmed to be effective for treating PsA and RA. Several studies have demonstrated that secukinumab also provides benefits for AS patients. Thus, we performed a meta-analysis of RCTs to evaluate the short-term efficacy and safety of secukinumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Yu, Ma, Jinhui, Ge, Juncheng, Wang, Bailiang, Yue, Debo, Wang, Weiguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7641709/
https://www.ncbi.nlm.nih.gov/pubmed/33192173
http://dx.doi.org/10.1155/2020/1639016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7641709/
https://www.ncbi.nlm.nih.gov/pubmed/33192173
http://dx.doi.org/10.1155/2020/1639016

Ejemplares similares